Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of AVROBIO, Inc. (NASDAQ: AVRO) resulting from allegations that AVROBIO may have issued materially misleading business information to the investing public.
If you purchased AVROBIO securities and would like to join the prospective action, please click “Join This Class Action.”
On May 3, 2021, before market hours, AVROBIO issued a press release entitled “AVROBIO Provides Regulatory Update on Investigational AVR-RD-01 for Fabry Disease” which announced that “AVROBIO can no longer pursue an accelerated approval pathway for AVR-RD-01 with the FAB-GT trial as currently designed[.]”
On this news, AVROBIO share prices fell $2.20 per share, or 18%, to close at $9.48 on May 3, 2021.
The Rosen Law Firm has been ranked among the top 4 law firms each year since 2013 for the number of successful securities class actions on behalf of investors. In 2019 alone, our firm recovered $438 million for investors.
Investors should carefully identify and select experienced counsel with a track record of success leading securities class actions. Often other firms issue press releases about class actions yet do not have comparable experience or resources.
Institutional Shareholders Services ranked the Rosen Law Firm # 1 for the number of securities class action recoveries in 2017.
The Rosen Law Firm represents investors throughout the globe. Our mission is to prosecute securities fraud class actions and protect shareholders’ rights.
